Targazyme Presents TZ-102 Cancer Immunotherapy Preclinical Results at the World Orphan Drug Congress
April 26, 2018 13:41 ET
|
Targazyme, Inc.
CARLSBAD, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Targazyme, Inc. a late clinical-stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy...
Targazyme, Inc. Receives FDA Clearance For a Phase 2 Study of Pediatric Cancer Patients Undergoing Stem Cell Transplantation For Treatment of Hematologic Malignancies
March 06, 2017 18:35 ET
|
Targazyme, Inc.
SAN DIEGO,CA--(Marketwired - March 06, 2017) - Targazyme Inc., a clinical stage biopharmaceutical company developing novel enzyme products to improve clinical efficacy, safety and cost of care...
Targazyme Inc. Receives Additional U.S Patent Award Designed to Improve Cell Therapy Clinical Efficacy Outcomes
January 18, 2017 16:16 ET
|
Targazyme, Inc.
CARLSBAD, CA--(Marketwired - January 18, 2017) - Targazyme Inc., a clinical stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy, safety and...
Targazyme, Inc. Receives FDA Clearance for a Phase II Haplo-Identical Transplant Study of Patients Undergoing Bone Marrow Transplantation for Treatment of Hematologic Malignancies
October 24, 2016 19:00 ET
|
Targazyme, Inc.
SAN DIEGO, CA--(Marketwired - October 24, 2016) - Targazyme Inc., a clinical stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy and cost of...
Targazyme Enrolls First Patient in Phase 1/2 Study of TZ101 Fucosylated Regulatory T Cells to Treat and Prevent Graft vs Host Disease in the Transplant Setting
July 20, 2016 18:45 ET
|
Targazyme, Inc.
SAN DIEGO, CA--(Marketwired - July 20, 2016) - Targazyme, Inc. a clinical-stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy outcomes for...
Targazyme and University of Minnesota Medical Center Initiate a Collaboration to Improve Regulatory T Cell Immunotherapy Outcomes for the Prevention and Treatment of Graft-Versus-Host-Disease
November 12, 2015 15:39 ET
|
Targazyme, Inc.
SAN DIEGO, CA--(Marketwired - November 12, 2015) - Targazyme, Inc. a clinical-stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy outcomes...
Targazyme Inc. Receives National Cancer Institute SBIR Award for Phase 2 Clinical Study of TZ101-Treated Regulatory T Cell Therapy for Prevention/Treatment of GVHD
July 27, 2015 15:48 ET
|
Targazyme, Inc.
SAN DIEGO, CA--(Marketwired - July 27, 2015) - Targazyme, Inc., a clinical-stage biopharmaceutical company developing novel enzyme technologies and products to improve efficacy outcomes for stem cell...
Targazyme, Inc., Announces FDA Concurrence on Targazyme's Special Protocol Assessment for a Planned Phase 3 Registration Trial for the Treatment of Patients With Hematologic Malignancies
April 23, 2015 12:02 ET
|
Targazyme, Inc.
SAN DIEGO, CA--(Marketwired - April 23, 2015) - Targazyme, Inc., announced today that the U.S. Food and Drug Administration (FDA) and Targazyme have reached concurrence on the company's Special...
Targazyme, Inc. and M.D. Anderson Cancer Center Receive FDA IND Clearance for Phase I/II Study of TZ101-Treated Regulatory T Cells to Prevent Graft vs Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation
March 17, 2015 15:24 ET
|
Targazyme, Inc.
SAN DIEGO, CA--(Marketwired - March 17, 2015) - Targazyme, Inc., a clinical stage biopharmaceutical company developing enzyme technologies and products to improve efficacy outcomes for a variety of...
Targazyme Inc. Receives Orphan Drug Designation to TZ101 for Use With Regulatory T Cells to Prevent & Reduce the Severity of Graft Versus Host Disease in Patients Eligible for Hematologic Stem Cell Transplantation
February 10, 2015 19:47 ET
|
Targazyme, Inc.
SAN DIEGO, CA--(Marketwired - February 10, 2015) - Targazyme Inc., a clinical-stage biopharmaceutical company developing enzyme technologies and products to improve efficacy outcomes for stem cell...